Terms & Conditions

No warranty and no liability

The material provided in this site is presented solely to improve public access to information about REVANCE. REVANCE will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations, expressed or implied, as to its accuracy or completeness. REVANCE will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in this site. REVANCE may change the content of this site including the terms that govern the use of this site at any time without prior notice but does not assume any responsibility to update the information provided herein.

Forward-looking information

Some of the statements on this site are forward looking. Such statements are inherently subject to known and unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of REVANCE and affiliates to be materially different from those expected or anticipated in the forward-looking statements. REVANCE has no responsibility to update the forward-looking statements contained in this site to reflect events or circumstances occurring after the date of publication. You must not rely on this information for investment decisions.

Links to third-party sites

Links to third party sites are provided for convenience only, and the inclusion of any links does not imply endorsement by REVANCE. The linked sites are not under control of REVANCE, and REVANCE disclaims any liability for all third-party information and the use of it.

Restrictions on use and submissions

The contents of this site are owned and controlled by REVANCE. No use of any of these may be made without the prior written consent of REVANCE, except for personal, non-commercial purposes. All submissions communicated to REVANCE through this site shall be and remain REVANCE’s property.

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.